Zabinostat - IngenOx Therapeutics
Alternative Names: AZD 9468; CXD101; ZabadinostatLatest Information Update: 28 Jun 2023
At a glance
- Originator AstraZeneca
- Developer Cancer Research UK; IngenOx Therapeutics; Merck Sharp & Dohme; National Institute for Health Research; Nuance Biotech; Oxford University Hospitals NHS Trust; Syneos Health; University College London
- Class Anti-inflammatories; Antihyperlipidaemics; Antineoplastics; Cardiovascular therapies; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer; Hodgkin's disease; Liver cancer; Peripheral T-cell lymphoma
- Phase I/II Diffuse large B cell lymphoma
- No development reported Lymphoma
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Lymphoma(Second-line therapy or greater) in China (PO, Capsule)
- 24 May 2023 IngenOx Therapeutics in collaboration with Chinese University of Hong Kong plans a phase II trial for Liver cancer (Second line therapy or greater, Combination therapy) in Hong Kong (PO) in September 2023 (NCT05873244)
- 13 Feb 2023 Ingenox Therapeutics initiates a phase II HACCA trial in Liver cancer (PO) (Ingenox Therapeutics pipeline, February 2023)